1. Alkermes will host a Q1 financial results call on May 1, 2025. 2. Conference will include a webcast with slides on Alkermes' website. 3. Company focuses on neuroscience with various treatment products in its portfolio. 4. Pipeline includes candidates for narcolepsy and idiopathic hypersomnia. 5. Alkermes is headquartered in Ireland with facilities in Massachusetts and Ohio.
While the financial results presentation is standard, no major developments are indicated yet.
The earnings call will provide insight but lacks groundbreaking news.
Upcoming earnings call can lead to price movement but lacks immediate significance.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Jamie Constantine
Investor Relations
+1 781 873 2402
SOURCE Alkermes plc